Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Journal of Animal and Veterinary Advances
Year: 2012  |  Volume: 11  |  Issue: 22  |  Page No.: 4161 - 4166

The Physiological and Biochemical Evaluation of Tulathromycin Premix in Pigs

Zhihui Hao, Yongda Zhao, Haoting Wu, Lihua Hao, Zhaopeng Ding, Fenfang Yang and Baohan Qu    

Abstract: The aim of the study was to investigated the influence of dietary inclusion of tulathromycin at 5 mg kg-1 die on haematological to provide an experiment support for the clinical use of this drug. Eighteen pigs were randomly allocated to three treatment groups. A further six pigs were left untreated as controls (group NTXL). Tulathromycin was administered twice by the oral route administrations of 5, 15, 25 mg kg-1 B.W. in three treatment groups on the 1st and the 4th day, respectively. Blood samples were taken from all animals on days 1, 17, 14 for serum chemical and hematology evaluation. Weight and temperature were measured from all animals at the same time. Comparisons of mean physical examination parameters between treatment and control groups over the 14 day study period revealed no significant differences (p>0.05). All pigs did not show any signs of discomfort after Premix. Hematology evaluation indicated that comparisons of RBC, WBC, HGB, HCT, MCV, MCH, MCHC and PLT between treatment and control groups also revealed no significant differences (p>0.05). AST, ALT, ALP, ALB, BUN were significantly higher in treated groups when compared with the control group (p<0.05) post-treatment. No significant differences as time goes on suggesting that a slight effect of injury on liver was caused by tulathromycin. The safety of tulathromycin Premix in target animal swine indicated that pigs were administered of 5-25 mg kg-1 B.W. via the oral route satisfied clinicians’ demands.

Fulltext    |   Related Articles   |   Back
  Related Articles

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility